Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy.
Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A, Greuter T, González-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D, Becker MD, Bamias G, Rieder F. Hedin CRH, et al. Among authors: schoepfer a. J Crohns Colitis. 2019 Apr 26;13(5):541-554. doi: 10.1093/ecco-jcc/jjy191. J Crohns Colitis. 2019. PMID: 30445584 Free article.
Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection.
Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Reinisch W, Chowers Y, Moran GW; European Crohn's and Colitis Organization (ECCO). Ben-Horin S, et al. Among authors: schoepfer a. J Crohns Colitis. 2010 Jun;4(2):194-8. doi: 10.1016/j.crohns.2009.11.001. Epub 2009 Nov 22. J Crohns Colitis. 2010. PMID: 21122505
Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals.
Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C; Swiss IBD Cohort Study. Voegtlin M, et al. Among authors: schoepfer am. J Crohns Colitis. 2010 Dec;4(6):642-8. doi: 10.1016/j.crohns.2010.07.008. Epub 2010 Aug 12. J Crohns Colitis. 2010. PMID: 21122574
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease.
Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM; Swiss IBD Cohort Study Group. Vavricka SR, et al. Among authors: schoepfer am. Inflamm Bowel Dis. 2012 Mar;18(3):496-505. doi: 10.1002/ibd.21719. Epub 2011 Apr 20. Inflamm Bowel Dis. 2012. PMID: 21509908
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet. Vavricka SR, et al. Among authors: schoepfer am. Inflamm Bowel Dis. 2011 Jul;17(7):1530-9. doi: 10.1002/ibd.21521. Epub 2010 Dec 22. Inflamm Bowel Dis. 2011. PMID: 21674709 Clinical Trial.
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; Swiss IBDnet and Swiss IBD Cohort Study Group. Vavricka SR, et al. Among authors: schoepfer am. Inflamm Bowel Dis. 2012 Aug;18(8):1523-30. doi: 10.1002/ibd.21888. Epub 2011 Oct 10. Inflamm Bowel Dis. 2012. PMID: 21987429
320 results